X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8) 8
oncology (7) 7
aged (6) 6
chemotherapy (6) 6
cisplatin (6) 6
female (6) 6
humans (6) 6
male (6) 6
medicine & public health (6) 6
middle aged (6) 6
adult (5) 5
cancer (5) 5
gastric cancer (5) 5
surgical oncology (5) 5
tumors (5) 5
stomach cancer (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer research (3) 3
care and treatment (3) 3
clinical trials (3) 3
colorectal cancer (3) 3
drug combinations (3) 3
drug therapy (3) 3
gastroenterology & hepatology (3) 3
japan (3) 3
oxonic acid - administration & dosage (3) 3
s-1 (3) 3
surgery (3) 3
tegafur - administration & dosage (3) 3
therapy (3) 3
treatment outcome (3) 3
abdominal surgery (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bevacizumab (2) 2
cancer therapies (2) 2
capecitabine (2) 2
carcinoma (2) 2
cisplatin - administration & dosage (2) 2
complications and side effects (2) 2
dosage and administration (2) 2
endothelial growth-factor (2) 2
expression (2) 2
gastrectomy (2) 2
gastroenterology (2) 2
guidelines (2) 2
leucovorin (2) 2
metastasis (2) 2
neoadjuvant therapy (2) 2
neoplasm staging (2) 2
organoplatinum compounds - administration & dosage (2) 2
original (2) 2
original article (2) 2
oxaliplatin (2) 2
patients (2) 2
prognosis (2) 2
research (2) 2
retrospective studies (2) 2
squamous cell carcinoma (2) 2
stomach neoplasms - drug therapy (2) 2
stomach neoplasms - pathology (2) 2
sunitinib (2) 2
survival (2) 2
adenocarcinoma (1) 1
adenocarcinoma - diagnosis (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - pathology (1) 1
adenocarcinoma - secondary (1) 1
adenocarcinoma - surgery (1) 1
adjuvant chemotherapy (1) 1
advanced hepatocellular-carcinoma (1) 1
alanine (1) 1
alanine transaminase (1) 1
anemia (1) 1
anemia - chemically induced (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - pharmacokinetics (1) 1
antitumor activity (1) 1
antitumor-activity (1) 1
appetite (1) 1
asian continental ancestry group (1) 1
avelumab (1) 1
biomarker (1) 1
c-reactive protein - analysis (1) 1
ca19-9 (1) 1
cancer patients (1) 1
carcinoma, squamous cell - diagnosis (1) 1
case-control studies (1) 1
chemoradiotherapy (1) 1
chemoradiotherapy - methods (1) 1
chemotherapy, adjuvant (1) 1
cisplatin - adverse effects (1) 1
cisplatin - pharmacokinetics (1) 1
cisplatin - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
BMC Cancer, ISSN 1471-2407, 05/2018, Volume 18, Issue 1, pp. 573 - 7
Journal Article
WORLD JOURNAL OF GASTROENTEROLOGY, ISSN 1007-9327, 09/2019, Volume 25, Issue 35, pp. 5334 - 5343
BACKGROUND Although pathological response is a common endpoint used to assess the efficacy of neoadjuvant chemotherapy (NAC) for gastric cancer, the problem of... 
REGRESSION | CRITERIA | Neoadjuvant therapy | GASTRECTOMY | Stomach neoplasm | TUMORS | Pathology | PHASE-II TRIAL | CISPLATIN | S-1 | Prognostic factor | Drug therapy | GASTROENTEROLOGY & HEPATOLOGY | CARCINOMA | Retrospective Study
Journal Article
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2014, Volume 32, Issue 2, pp. 261 - 270
Background This phase I, dose-finding study evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of sunitinib plus... 
Sunitinib | Phase I | Medicine & Public Health | Dose-finding | Oncology | Pharmacology/Toxicology | Gastric cancer | MULTICENTER | GUIDELINES | ANTITUMOR-ACTIVITY | SU11248 | CHEMOTHERAPY | ONCOLOGY | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | RECEPTORS | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Pyrroles - pharmacokinetics | Cisplatin - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Stomach Neoplasms - metabolism | Male | Indoles - administration & dosage | Cisplatin - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Pyrroles - administration & dosage | Pyrroles - adverse effects | Adult | Female | Oxonic Acid - pharmacokinetics | Angiogenesis Inhibitors - adverse effects | Tegafur - adverse effects | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Tegafur - pharmacokinetics | Oxonic Acid - adverse effects | Asian Continental Ancestry Group | Maximum Tolerated Dose | Indoles - adverse effects | Cisplatin - adverse effects | Tegafur - administration & dosage | Indoles - pharmacokinetics | Aged | Drug Combinations | Complications and side effects | Dosage and administration | Research | Drug therapy | Stomach cancer | Cisplatin | Studies | Clinical trials | Pharmaceutical sciences | Index Medicus | Phase I Studies
Journal Article
Oncology, ISSN 0030-2414, 10/2017, Volume 93, Issue 5, pp. 329 - 335
Purpose: Regorafenib improves survival in chemorefractory metastatic colorectal cancer (mCRC) patients. However, regorafenib induces various adverse events... 
Clinical Study | Regorafenib | CA19-9 | Colorectal cancer | Predictive marker | ADVANCED HEPATOCELLULAR-CARCINOMA | BIOMARKER | PAZOPANIB | BEVACIZUMAB | TREATED PATIENTS | SORAFENIB | RENAL-CELL CARCINOMA | ONCOLOGY | PHASE-3 TRIAL | SUNITINIB | HYPERTENSION
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.